F

Fulcrum Therapeutics
D

FULC

3.25500
USD
0.28
(9.23%)
Market Closed
Volume
22,794
EPS
-0
Div Yield
-
P/E
-11
Market Cap
175,570,342
News

Title: Fulcrum Therapeutics

Sector: Healthcare
Industry: Biotechnology
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.